Stay updated on Continuation Therapy in Advanced NSCLC Clinical Trial
Sign up to get notified when there's something new on the Continuation Therapy in Advanced NSCLC Clinical Trial page.

Latest updates to the Continuation Therapy in Advanced NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe ClinicalTrials.gov page’s footer revision identifier changed from v3.8.0 to v3.8.1; the study details remain unchanged.SummaryDifference0.1%

- Check9 days agoChange DetectedThe page now displays the completed Phase II trial record for pembrolizumab plus chemotherapy in advanced non-small-cell lung cancer, including its study design, participant criteria, outcome measures, locations, and supporting documents.SummaryDifference53%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check30 days agoChange DetectedA notice about NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence” appears above the page. The clinical trial record itself still displays a 403 error.SummaryDifference1%

- Check37 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.1 to v3.7.2. The page continues to display a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check44 days agoChange DetectedThe site revision label in the footer changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Continuation Therapy in Advanced NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Continuation Therapy in Advanced NSCLC Clinical Trial page.